BPC-157 Dosage Per Body Weight (Chart)

The standard BPC-157 dose in rodent studies is 10 mcg/kg body weight, administered intraperitoneally (directly into the abdominal cavity) once daily. This dose produced tendon healing, muscle repair, gut protection, and neuroprotective effects across dozens of published studies (Chang et al., Life Sci, 2011).

The dose range across all published BPC-157 animal studies spans 6 to 50 mcg/kg. Most studies cluster around 10 mcg/kg. A 2019 systematic review cataloged the dosing protocols across the literature and confirmed this range (Gwyer et al., Cell Tissue Res, 2019).

The intraperitoneal route used in animals achieves near-100% bioavailability. Humans use subcutaneous injection, which reaches approximately 90%. This difference matters when calculating equivalent doses.

The FDA-recommended method for converting animal doses to human equivalent doses (HED) uses body surface area (BSA) normalization, not simple weight scaling. The formula was published by Reagan-Shaw et al. (FASEB J, 2008):

HED (mcg/kg) = Animal dose (mcg/kg) x (Animal Km / Human Km)

The Km factor accounts for metabolic rate differences between species. For rats, Km = 6. For humans, Km = 37.

Calculation: 10 mcg/kg x (6 / 37) = 1.62 mcg/kg human equivalent dose.

For a 91 kg (200 lb) human: 1.62 x 91 = approximately 148 mcg/day. This is the conservative floor, the minimum dose expected to produce biological activity based on the animal data. For a dedicated breakdown at this weight, see our BPC-157 dosage guide for a 200 lb male.

The BSA-converted minimum (1.6 mcg/kg) gives a conservative starting point. The standard community dose of 250 to 500 mcg/day runs 2 to 4 times above this floor. Three factors explain the gap.

First, bioavailability. Rat studies use intraperitoneal injection (near 100% absorption). Subcutaneous injection in humans reaches approximately 90%. The slight reduction justifies a modest upward adjustment.

Second, safety margin. BPC-157 shows no toxicity even at doses far exceeding the therapeutic range in animal models. The 2025 human safety pilot administered 10 to 20 mg intravenously (40 to 80 times the typical subcutaneous dose) with no adverse effects (Staresinic et al., Altern Ther Health Med, 2025). This wide therapeutic window allows practitioners to dose above the minimum without safety concerns.

Third, the threshold activation model. BPC-157 works by triggering receptor pathways (FAK-paxillin, VEGF, FGF, NO system), not by maintaining a specific plasma concentration (Seiwerth et al., Curr Pharm Des, 2018). Dosing above the threshold ensures consistent receptor activation even with individual absorption variability.

Conservative (1.6 mcg/kg): The human equivalent dose calculated from the BSA method. This is the mathematical floor derived from the standard rat dose of 10 mcg/kg.

Low (5 mcg/kg): A direct mcg/kg extrapolation at the lower end of the animal study range. Falls within the community standard for most body weights.

Standard (7.5 mcg/kg): The midpoint of the commonly cited animal dose range. For a 170 lb person, this yields 580 mcg, slightly above the typical 500 mcg clinical dose.

High (10 mcg/kg): The full animal study dose applied to human body weight without BSA conversion. Used by some practitioners for severe injuries or post-surgical recovery.

Clinical Practice: What peptide therapy providers actually prescribe. The convergence zone (250 to 500 mcg) sits at the low-to-standard range for medium-weight individuals. For BPC-157 benefits across different conditions, the clinical dose appears sufficient regardless of body weight.

The Zhang et al. pharmacokinetic study administered BPC-157 intravenously and subcutaneously to male and female beagle dogs. Plasma concentration curves overlapped. Clearance rates, half-life, and area under the curve (AUC) showed no statistically significant gender difference.

No human pharmacokinetic study exists for BPC-157 in either sex. Body composition differences (women typically carry higher body fat percentage) could theoretically affect subcutaneous absorption rates, but no data supports adjusting the dose based on this. For more on BPC-157 in female physiology, see BPC-157 benefits for women.

The overlap range (160 to 180 lbs) uses identical dosing for both genders. The slight upward adjustment to 500 mcg for heavier men reflects the general clinical practice pattern, not gender-specific pharmacology. Hormonal cycle phase does not appear to affect BPC-157 metabolism based on available data, though no human study has directly tested this.

Subcutaneous injection delivers approximately 90% bioavailability. The weight chart above applies directly to this route. The standard protocol:

250 to 500 mcg injected subcutaneously once or twice daily. Inject near the injury site for local tissue repair, or in the abdomen for systemic effects. For injection site guidance, see where to inject BPC-157 and how to inject BPC-157.

Peak plasma concentration occurs within 15 to 30 minutes. The half-life is under 30 minutes, which is why some protocols call for twice-daily dosing during acute recovery phases.

BPC-157 is uniquely stable in gastric acid, unlike most peptides that degrade in the stomach within minutes. Animal studies used oral doses of 10 to 200 mcg/kg with demonstrated efficacy for gut healing, liver protection, and systemic effects (Sikiric et al., Curr Pharm Des, 2018).

Oral bioavailability is lower than injection due to first-pass metabolism. Community oral doses run higher to compensate:

Oral dosing shows more weight sensitivity than injection. A larger body means greater volume of distribution, diluting the peptide that survives first-pass metabolism. The slight upward adjustment for heavier individuals is more justified here than for subcutaneous injection.

Both the arginate and acetate salt forms are available for oral use. Arginate may offer marginally better gastric stability.

Think of a light switch. Flipping it activates the circuit. Pushing harder does not make the light brighter. BPC-157 works like that switch. It binds to FAK-paxillin pathway components, upregulates VEGF and FGF receptors, and modulates the nitric oxide system (Seiwerth et al., Curr Pharm Des, 2018). Once the receptor is activated, additional peptide molecules do not amplify the signal.

This distinguishes BPC-157 from drugs like antibiotics or anesthetics, where higher body weight genuinely requires higher doses to maintain effective plasma concentration. Those drugs work through concentration-dependent mechanisms. BPC-157 works through threshold activation. Once the threshold is met, more peptide does not equal more healing.

Some animal models show reduced efficacy at very high BPC-157 doses. The dose-response curve forms an inverted U: efficacy rises with dose, peaks, then declines. This has been observed across several of Sikiric's published studies.

This pattern argues against aggressive weight-based scaling for heavy individuals. A 280 lb person taking 1,273 mcg (the "high" column) may not heal faster than one taking 500 mcg. They may actually see diminished returns. The flat clinical dose of 250 to 500 mcg sits squarely at the peak of the dose-response curve for most people.

The only published human BPC-157 data comes from Staresinic et al. (2025). Two adult participants received 10 mg and 20 mg intravenously. These doses are 40 to 80 times the typical 250 mcg subcutaneous dose. Dosing was flat, not weight-adjusted (Staresinic et al., Altern Ther Health Med, 2025).

No adverse effects were observed. Plasma cleared within 24 hours. While two participants cannot establish safety in any rigorous sense, the study confirms the extraordinarily wide therapeutic window and the precedent for flat dosing in human use.

For a broader perspective on peptide safety, see our peptide safety guide.

Adding more water makes each unit contain less peptide. This gives you finer dose control but uses the vial faster. Most users add 2 mL for the best balance of precision and vial longevity.

Step 1: Convert weight. 170 lbs / 2.2 = 77 kg.

Step 2: Calculate dose. 77 kg x 5 mcg/kg = 385 mcg.

Step 3: Choose reconstitution. 5 mg vial + 2 mL bacteriostatic water = 2,500 mcg/mL.

Step 4: Calculate volume. 385 mcg / 2,500 mcg/mL = 0.154 mL = approximately 15 units on an insulin syringe.

Step 5: Round practically. Draw to the 15-unit mark. The actual dose is 375 mcg, close enough to the target 385 mcg. Rounding to the nearest 5 units avoids the dosing errors that come from trying to eyeball fractional markings.

For automated calculations, plug your numbers into the BPC-157 dosage calculator.